Related Experiment Videos
Intraluminal low-dose rate brachytherapy for malignant endobronchial obstruction.
T C Lo1, J F Beamis, R S Weinstein
1Department of Radiation Oncology, Lahey Clinic Medical Center, Burlington, MA 01805.
Summary
Intraluminal brachytherapy using iridium-192 seeds effectively treated malignant airway tumors, with higher doses significantly improving clinical response. This low-dose rate radiotherapy demonstrated well-tolerated outcomes and acceptable complication rates.
Area of Science:
- Oncology
- Radiotherapy
- Pulmonology
Background:
- Malignant tumors of the endobronchial and endotracheal airways present significant treatment challenges.
- External beam radiotherapy is often a primary treatment, but local control can be difficult.
- Intraluminal brachytherapy offers a targeted approach for these challenging tumors.
Purpose of the Study:
- To evaluate the efficacy and safety of low-dose rate iridium-192 intraluminal brachytherapy for endobronchial and endotracheal malignant tumors.
- To identify factors influencing treatment response, including radiation dose and prior therapies.
- To assess the tolerability and complication profile of this treatment modality.
Main Methods:
- A retrospective analysis of 105 intraluminal brachytherapy treatments using low-dose rate iridium-192 seeds in 87 patients between October 1985 and October 1989.
- Patients treated for primary lung carcinoma, metastatic disease, or extension from cervical esophageal carcinoma were included.
- Clinical and bronchoscopic outcomes were assessed, along with radiation dose delivered and prior treatment history.
Main Results:
- Clinical or bronchoscopic improvement was observed in 59% of patients.
- Patients receiving a radiation dose greater than 2500 cGy at a 2 cm radius showed a significantly higher response rate (77%) compared to those receiving less (38%) (p = 0.001).
- No significant difference in response was noted across tumor types, but a trend favored patients undergoing Nd:YAG laser bronchoscopy prior to brachytherapy. Treatments were well tolerated with low serious complication rates.
Conclusions:
- Low-dose rate iridium-192 intraluminal brachytherapy is an effective and well-tolerated treatment for malignant endobronchial and endotracheal tumors.
- Higher radiation doses are associated with improved clinical response.
- This technique can be safely integrated into treatment protocols, including for patients who have received prior external beam radiotherapy.